2018
DOI: 10.22270/jddt.v8i2.1682
|View full text |Cite
|
Sign up to set email alerts
|

Multidrug Resistant Tuberculosis in Children in the Democratic Republic of Congo: First Experience With a Short Treatment Course in a University Hospital

Abstract: Background: A short treatment course for multidrug-resistant tuberculosis (MR-TB) is not yet well codified in children in the Democratic Republic of Congo (DRC). The objective of this study was to evaluate a short MR-TB treatment course in children. Methods: A prospective study was performed from April 2015 (corresponding to the inclusion) through April 2017 (and the later initiation time point was April 2016) in the University Clinics of Kinshasa. Enrolled children were aged 0 to 15 years. The treatment durat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2019
2019

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 19 publications
0
1
0
Order By: Relevance
“…Currently the treatment given for the CTB is the same as that for pulmonary TB and consists of long term two phase multidrug therapy i.e. isoniazid, rifampicin, ethambutol and pyrazinamide for 2 months in initial phase and then isoniazid and rifampicin for the next 4 months as second phase of treatment 2,4 . The antitubercular drugs (isoniazid, rifampicin, ethambutol and pyrazinamide) ISSN: 2250-1177…”
Section: Mycobacteriummentioning
confidence: 99%
“…Currently the treatment given for the CTB is the same as that for pulmonary TB and consists of long term two phase multidrug therapy i.e. isoniazid, rifampicin, ethambutol and pyrazinamide for 2 months in initial phase and then isoniazid and rifampicin for the next 4 months as second phase of treatment 2,4 . The antitubercular drugs (isoniazid, rifampicin, ethambutol and pyrazinamide) ISSN: 2250-1177…”
Section: Mycobacteriummentioning
confidence: 99%